CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 9 enrolled
Drug / intervention
calcitrioldrug
Likely dose
calcitriol 0.25 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00427804
NCT00427804N/ACompleted
CompareCT.gov

Tumor Necrosis Factor-α Induces Vitamin D Resistance in Small Intestinal Calcium Absorption

Atlanta VA Medical Center·interventional·Posted Jan 29, 2007·Updated Feb 4, 2013

In Brief

A clinical study evaluating calcitriol for Rheumatoid Arthritis and Crohn's Disease. Completed, enrolled 9 participants across 1 site.

Detailed Summary

This study is a pilot study to determine whether patients with TNFα excess have decreased calcium absorption in response to calcitriol (1,25-dihydroxyvitamin D, the active form of vitamin D) compared to normal controls. This initial pilot study is being done to determine if it is feasible to conduct a study where TNFα could be blocked (e.g., by anti-TNFα therapy such as Enbrel® or Remicade®) to improve vitamin D dependant calcium absorption and thus bone health.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis, Crohn's Disease
CountriesUnited States
CollaboratorsEmory University

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 29, 2007
Enrollment StartJan 1, 2007
Primary CompletionAug 1, 2009
Study CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 19.4 years ago

Interventions

calcitrioldrug

0.25 mcg PO BID for 1 week for low dose then 0.25 mcg PO BID for high dose